Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial

References

• Carbonell EsteveJLAcostaRHerediaBPérezYCastañedaMCHernándezAVMifepristone for the treatment of uterine leiomyomas: a randomized controlled trialObstet Gynecol200811251029103618978102
   PubMed Web of Science ®Google Scholar
• Carbonell EsteveJLQuiróz RámirezGMBorgeACastellón ZapataLEAragónWCTomasiGMifepristona 5 mg frente a 10 mg diarios en el tratamiento del leiomioma. Ensayo clínico aleatorizado [Mifepristone 5 mg versus 10 mg daily in the treatment of leiomyoma. Randomized Trial]Progresos de Obstetricia y Ginecología20105325158 Spanish
   Google Scholar
• CarbonellJLAcostaRPérezYYeroMCSeiglerIHerediaBEvolución del leiomioma uterino después del tratamiento con mifepristona. Ensayo clínico aleatorizado [Evolution of uterine leiomyoma after treatment with mifepristone: a randomized clinical trial]Progresos de Obstetricia y Ginecología2010536231236 Spanish
   Google Scholar
• Carbonell EsteveJLAcostaRHerediaBMifepristona para tratamiento del fibroma uterino [Mifepristone to treat uterine fibroids]Revista Cubana de Obstetricia y Ginecología2010362 Spanish
   Google Scholar
• EsteveJLAcostaRPérezYCamposRHernándezAVTexidóCSTreatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trialEur J Obstet Gynecol Reprod Biol2012161220220822269473
   PubMed Web of Science ®Google Scholar
• Carbonell EsteveJLRiverónAMCanoMMifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgeryInt J Womens Health20124758422448109
   PubMedGoogle Scholar
• EisingerSHMeldrumSFicellaKle RouxHDGuzickDSLow-dose mifepristone for uterine leiomyomataObstet Gynecol2003101224325012576246
   PubMed Web of Science ®Google Scholar
• EisingerSHBonfiglioTFiscellaKMeldrumSGuzickDSTwelvemonth safety and effcacy of low-dose mifepristone for uterine myomasJ Minim Invasive Gynecol200512322723315922980
   PubMed Web of Science ®Google Scholar
• FiscellaKEisingerSHMeldrumSFengCFisherSGGuzickDSEffect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trialObstet Gynecol200610861381138717138770
   PubMed Web of Science ®Google Scholar
• EngmanMGranbergSWilliamsARMengCXLalitkumarPGGemzell-DanielssonKMifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trialHum Reprod20092481870187919389793
   PubMed Web of Science ®Google Scholar
• YangYZhengSLiKTreatment of uterine leiomyoma by two different doses of mifepristoneZhonghua Fu Chan Ke Za Zhi19963110624626 Chinese9275461
   PubMedGoogle Scholar
• ZengCGuMHuangHA clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristoneZhonghua Fu Chan Ke Za Zhi199833849049210806751
   PubMedGoogle Scholar
• HornFMBlitheDLProgesterone receptor modulators and the endometrium: changes and consequencesHum Reprod Update200713656758017630398
   PubMed Web of Science ®Google Scholar
• MutterGLBergeronCDeligdischThe spectrum of endometrial pathology induced by progesterone receptor modulatorsMod Pathol200821559159818246050
   PubMed Web of Science ®Google Scholar
• SpiesJBCoyneKGuaou GuaouNBoyleDSkyrnarz-MurphyKGonzalvesSMThe UFS-QOL, a new disease-specifc symptom and health-related quality of life questionnaire for leiomyomataObstet Gynecol200299229030011814511
   PubMed Web of Science ®Google Scholar
• BagariaMSunejaAVaidNBGuleriaKMishraKLow-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trialAust N Z J Obstet Gynecol20094917783
   Web of Science ®Google Scholar
• FaulFG*Power [computer program]. Version 3.0.10KielUniversitat Kiel. Germany
   Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, US Department of Health and Human Services, Center for Biologics Evaluation and ResearchGuidance for Industry: Drug-Induced Liver Injury; Premarketing Clinical EvaluationSilver Spring and Rockville, MDUS Department of Health and Human Services, Food and Drug Administration, US Department of Health and Human Services, Center for Biologics Evaluation and Research2009 Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdfAccessed November 12, 2012
   Google Scholar
• SpitzIMMifepristone: where do we come from and where are we going? Clinical development over a quarter of a centuryContraception201082544245220933118
   PubMed Web of Science ®Google Scholar
• SilverbergSGKurmanRJEndometrial carcinomaAtlas of Tumor Pathology: Tumors of the Uterine Corpus and Gestational Trophoblastic DiseaseWashington DCArmed Forces Institutes of Pathology19914789
   Google Scholar
• ScullyREBonfiglioTAKurmanRJSilverbergSGWilkinsonEJUterine corpusHistological Typing of Female Genital Tract Tumors2nd edNew York, NYSpringer-Verlag19941331
   Google Scholar
• MutterGLEIN overview [web page on the Internet]Harvard Medical School and Brigham Women’s Hospital Available at: http://www.endometrium.org/EIN%20Central/FramePages/EINOverviewFrame%28ModuleI%29.htmAccessed Jan 2008
   Google Scholar
• BairdDTBrownACritchleyHOWilliamsARLinSChengLEffect of long-term treatment with low-dose mifepristone on the endometriumHum Reprod2003181616812525442
   PubMed Web of Science ®Google Scholar
• BrownAChengLLinSBairdDTDaily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 daysJ Clin Endocrinol Metab2002871637011788624
   PubMed Web of Science ®Google Scholar
• SpiesJBWarrenEHMathiasSDWalshSMRothARPentecostMJUterine fibroid embolization: measurement of health-related quality of life before and after therapyJ Vasc Interv Radiol199910101293130310584643
   PubMed Web of Science ®Google Scholar
• FiscellaFBonfiglioTWintersPEisingerSHFiscellaKDistinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristoneHum Pathol201142794795321315422
   PubMed Web of Science ®Google Scholar